$Enanta Pharmaceuticals (ENTA.US)$ Enanta Pharmaceuticals An...

Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)

Positive
Achieved primary endpoint with 1.4 log viral load decline at Day 5 in Part 2
Demonstrated favorable safety profile with no treatment discontinuations
Received FDA Fast Track designation
Successfully achieved target drug exposure levels across all age groups
Showed 1.2 log viral load reduction in early-treated patients

Negative
No significant difference in symptoms between zelicapavir and placebo using ReSViNET assessment
symptom data available from proprietary RESOLVE-P tool (only 15 patients)